ARMP Armata Pharmaceuticals Inc. Stock Quote

ARMP [AMEX]

Index	-	P/E	-	EPS (ttm)	-1.42	Insider Own	75.38%	Shs Outstand	18.44M	Perf Week	1.71%
Market Cap	102.29M	Forward P/E	-	EPS next Y	-1.15	Insider Trans	0.00%	Shs Float	6.88M	Perf Month	-9.35%
Income	-22.20M	PEG	-	EPS next Q	-0.32	Inst Own	8.60%	Short Float	0.69%	Perf Quarter	-25.40%
Sales	0.80M	P/S	127.86	EPS this Y	45.70%	Inst Trans	0.38%	Short Ratio	1.99	Perf Half Y	27.13%
Book/sh	1.02	P/B	4.09	EPS next Y	-7.50%	ROA	-49.60%	Target Price	-	Perf Year	29.91%
Cash/sh	0.39	P/C	10.66	EPS next 5Y	-	ROE	-83.20%	52W Range	2.56 - 10.48	Perf YTD	39.70%
Dividend	-	P/FCF	-	EPS past 5Y	65.60%	ROI	-	52W High	-60.21%	Beta	1.35
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	11.60%	Gross Margin	-	52W Low	62.89%	ATR	0.18
Employees	59	Current Ratio	1.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.13	Volatility	1.64% 4.80%
Optionable	No	Debt/Eq	0.04	EPS Q/Q	25.20%	Profit Margin	-	Rel Volume	0.18	Prev Close	4.10
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 18 AMC	Payout	-	Avg Volume	23.91K	Price	4.17
Recom	1.70	SMA20	-0.73%	SMA50	-13.05%	SMA200	6.79%	Volume	4,187	Change	1.71%

Jun-19-19

Initiated

Ladenburg Thalmann

Buy

Mar-18-21 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update PR Newswire
Mar-17-21 04:01PM	Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva PR Newswire
Mar-16-21 11:01AM	Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire
Jan-27-21 07:01AM	Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs PR Newswire
Dec-09-20 07:30AM	Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors PR Newswire
Nov-16-20 11:10PM	Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts Simply Wall St. -13.97%
Nov-15-20 07:17AM	Earnings Beat: Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
Nov-12-20 04:05PM	Armata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update PR Newswire +7.95%
Oct-29-20 07:30AM	Armata Pharmaceuticals Issues Letter to Shareholders PR Newswire +7.00%
Oct-26-20 07:30AM	Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development PR Newswire
Oct-15-20 07:30AM	Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections PR Newswire +8.86%
Sep-29-20 07:30AM	Armata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance Congress PR Newswire
Sep-11-20 07:30AM	Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences PR Newswire
Aug-13-20 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update PR Newswire
Jun-30-20 06:05AM	Here's Why We're Watching Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Situation Simply Wall St.
Jun-17-20 07:30AM	Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections PR Newswire +10.33%
May-14-20 04:05PM	Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update PR Newswire
Apr-28-20 08:00AM	Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector PR Newswire
Mar-30-20 07:30AM	Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. PR Newswire
Mar-19-20 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update PR Newswire -6.46%
Mar-18-20 08:00AM	Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation PR Newswire +10.94%
Feb-13-20 08:00AM	Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc. PR Newswire
Jan-29-20 08:04AM	Company News For Jan 29, 2020 Zacks -26.80%
Jan-28-20 07:00AM	Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs PR Newswire +73.84%
Nov-12-19 04:05PM	Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update PR Newswire
Oct-31-19 10:52AM	We're Keeping An Eye On Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Rate Simply Wall St.
07:05AM	Armata Pharmaceuticals Issues Letter to Shareholders PR Newswire
Oct-21-19 07:05AM	Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive PR Newswire
Oct-16-19 07:05AM	Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director PR Newswire
Oct-10-19 04:05PM	Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D. PR Newswire
Sep-19-19 07:05AM	Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference PR Newswire
Sep-12-19 09:00AM	Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa PR Newswire
Aug-14-19 04:05PM	Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update PR Newswire
Aug-02-19 03:27PM	How Much Of Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) Do Institutions Own? Simply Wall St.
Aug-01-19 10:30AM	Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference PR Newswire
Jun-18-19 07:01AM	Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York PR Newswire
Jun-03-19 07:01AM	Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada PR Newswire -5.96%
May-28-19 07:01AM	Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient PR Newswire +31.67%

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience